The first quarter of 2026 brought an agreement on the EU Pharma Package, joint FDA/EMA guidelines for AI in pharmaceuticals, finalization of Annex 22, and a full year of compliance with the new Annex 1. What this means for PAT/QbD teams in pharmaceuticals and chemistry.